Drug recall · October 6, 2021
Ruzurgi recall
Why: Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01.
- Lots / codes
Lot #: 18038, 18039, Exp 03/2023; 18079, Exp 05/2023
- Quantity
- 2,324 bottles
- Company
- Jacobus Pharmaceutical Company Inc., Plainsboro, NJ
- Distribution
- Product was distributed within the USA and Canada. Control # 18038, was distributed to Canada only.
- Initiated
- September 9, 2021 · Voluntary: Firm initiated
- Classified
- October 8, 2021
- Reported
- October 6, 2021
- Ended
- February 18, 2022
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.